Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 04, 2022 07:30 ET | Source: Harpoon Therapeutics

Harpoon Therapeutics Appoints Luke Walker, M.D., as Chief Medical Officer

SOUTH SAN FRANCISCO, Calif., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced the...
September 19, 2022 16:05 ET | Source: Harpoon Therapeutics

Harpoon Therapeutics Appoints Lauren Silvernail to Board of Directors

SOUTH SAN FRANCISCO, Calif., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced...
September 01, 2022 07:30 ET | Source: Harpoon Therapeutics

Harpoon Therapeutics to Participate in Three Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced...
August 10, 2022 16:01 ET | Source: Harpoon Therapeutics

Harpoon Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Presented encouraging interim data for anti-DLL3 T cell engager HPN328 from ongoing dose escalation clinical trial at the 2022 ASCO Annual Meeting Portfolio prioritization and resource alignment...
August 02, 2022 07:30 ET | Source: Harpoon Therapeutics

Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced...
July 06, 2022 07:30 ET | Source: Harpoon Therapeutics

Harpoon Therapeutics Expands Leadership Team

Appointments named for two key executive leadership positions in human resources and translational medicine SOUTH SAN FRANCISCO, Calif., July 06, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc....
May 26, 2022 17:00 ET | Source: Harpoon Therapeutics

Harpoon Presents Interim Data from Ongoing Dose Escalation Portion of T Cell Engager HPN328 Clinical Trial at 2022 ASCO Annual Meeting

Clinically active and well tolerated in patients with solid tumorsFavorable safety profile emerging: 22% of patients experienced Grade 1-2 cytokine release syndrome (CRS); no Grade 3 or higher CRSOne...
May 12, 2022 16:05 ET | Source: Harpoon Therapeutics

Harpoon Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

SOUTH SAN FRANCISCO, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today reported...
May 02, 2022 09:00 ET | Source: Harpoon Therapeutics

Harpoon Therapeutics and Roche to Collaborate on Clinical Trials to Study Novel Immuno-Oncology Combination for Small Cell Lung Cancer

SOUTH SAN FRANCISCO, Calif., May 02, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that...
April 12, 2022 07:30 ET | Source: Harpoon Therapeutics

Harpoon Therapeutics Presents Preclinical Data for TriTAC-XR Platform that Supports Potential for Improved Safety by Minimizing Cytokine Release Syndrome

SOUTH SAN FRANCISCO, Calif., April 12, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today presented a...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right